Search
News
Apple and Tencent Agree to 15% Fee on WeChat Mini Game Purchases - Bloomberg
Tencent Holdings Ltd. has agreed a deal with Apple Inc. that will see the iPhone maker handle payments and take a 15% cut of purchases in WeChat mini games and apps, according to people familiar with the discussions.Resolving the issue, under negotiation between the two tech titans for over a year, ...Tiger News
Thu, Nov 13
Premarket Movers | Firefly Aerospace Surges 18%; Cisco Jumps 7%; Storage Shares Pull Back with SanDisk Down 6%, Micron Down 3%
Cisco Systems shares were up 7% in premarket trading on Thursday, after the company raised full-year forecasts for profit and revenue.Cisco is betting on robust demand for its networking equipment driven by multi-billion-dollar data centre expansions amid the artificial intelligence boom.Storage sha...Tiger News
Thu, Nov 13
Adicon to Acquire Crown Bioscience for US$204 Million, Creating a Global End-to-End Laboratory Service Platform
Hangzhou, China – Nov.13, 2025 – Adicon Holdings Limited (“Adicon”, 9860.HK), a leading independent clinical laboratory service provider in China and a portfolio company of global investment firm Carlyle, today announced that it has entered into a definitive share purchase agreement with JSR Life Sciences, LLC to acquire 100% of the issued shares of Crown Bioscience International (“Crown Bioscience”) for a base consideration of US$204 million (inclusive of earn-out payments), and subject to customary post-closing adjustments. The transaction is expected to close in mid-2026.Crown Bioscience is a global contract research organization (CRO) providing discovery, preclinical and translational platforms and services to advance oncology and immuno-oncology drug discovery and development. Following the completion of the transaction, Crown Bioscience will operate as a standalone entity under Adicon’s ownership, maintaining its scientific leadership and global customer relationships while benefiting from Adicon’s complementary capabilities and strategic resources. Adicon is well positioned to capture the growth from both China’s expanding demand for precision diagnostics and global trends in biopharmaceutical innovation.Creation of a global end-to-end laboratory service platformThe transaction marks a transformative milestone in Adicon’s strategic journey – from a leading China-based diagnostics platform to a global end-to-end laboratory services provider that bridges diagnostics, clinical development, and preclinical research. By combining Adicon’s nationwide clinical laboratory network in China with the Crown Bioscience’s global preclinical and translational expertise in oncology and immuno-oncology, the partnership will enable enhanced biomarker strategies, improve translational predictivity, and help biopharma sponsors advance promising therapies toward clinical development with greater confidence and speed.Leading capabilities in preclinical In Vivo and In Vitro oncology research With the world’s largest patient-derived xenograft (PDX) model collection and advanced tumor organoid platforms that deliver exceptional translatability and patient response predictivity, Crown Bioscience’s expertise spans in vitro, in vivo, and ex vivo methods. Adicon will continue to support these innovative capabilities to help biopharma partners accelerate oncology drug development and improve confidence in translational decision-making.Expanding Global Reach and Industry PartnershipsCrown Bioscience serves more than 1,100 biopharmaceutical and biotechnology companies globally, including all of the top 20 global pharmaceutical companies. Combining their global client base with Adicon’s strong relationships with hospitals and healthcare institutions across China will create an innovation ecosystem that connects early discovery with clinical validation. Following completion, approximately 23.1 % of Adicon’s combined revenue will be generated outside China, underscoring its evolution into a truly international platform.Strengthening Financial Profile and Long-Term GrowthThe transaction adds a new complementary growth engine to Adicon’s resilient diagnostics business. Stable cash flow from its independent clinical laboratory (ICL) operations, combined with Crown Bioscience’s high-growth and high-margin CRO services, provides a balanced and scalable business model. This combination is expected to unlock new revenue opportunities, and create long-term shareholder value.Management CommentaryMs. Yang Ling, Chairwoman of Adicon and Head of Asia Healthcare at Carlyle, commented, “This acquisition represents an important milestone in Adicon’s growth journey. With Crown Bioscience’s world-class CRO capabilities, Adicon is expanding its reach across the global healthcare value chain – from clinical diagnostics to drug discovery and translational research. This transaction reinforces Adicon’s vision to become a trusted partner for biopharma innovation and precision diagnostics.”"This transition marks a pivotal moment for Crown Bioscience," said John Gu, CEO of Crown Bioscience. "With Adicon’s strong support and the backing of Carlyle’s global network and resources, we are poised to accelerate innovation in translational oncology and expand our capabilities across key global markets. From our new Model Development Center in North Carolina to our advanced imaging and biomarker operations in the UK, we are deepening our commitment to providing clients with local access to cutting-edge science. Through our EU, UK, APAC and US initiatives, we’re institutionalizing best practices and scientific excellence across all regions, ensuring that every study reflects the same high standards and delivers the trusted Crown experience our partners rely on."Transaction DetailsTotal Purchase Price: US$204 million (subject to earnout adjustments, and customary adjustments for working capital, indebtedness, transaction expenses, and cash) Earn-out Price: Up to US$84 million, contingent on performance Outside Date: 9 months plus automatic extension for 3 months. Closing would be subject to customary conditions, including shareholder approval and regulatory clearances Structure: 100% equity acquisition; Crown Bioscience to become a wholly owned subsidiary of Adicon upon completionAbout AdiconAdicon Holdings Limited (HKEX: 9860.HK) is one of China’s leading independent clinical laboratory service providers, offering comprehensive diagnostic testing services primarily to hospitals, health check centers and biopharmaceuticals through an integrated network of self-operated laboratories across the country. The company provides a broad testing portfolio covering routine and esoteric tests across multiple disease areas, supported by internationally accredited laboratories that meet ISO15189 standards. With a proven track record of operational excellence, national coverage, and strong quality assurance, Adicon has established itself as a trusted partner to healthcare institutions and professionals, contributing to the advancement of precision diagnostics and improved healthcare outcomes in China.About Crown BioscienceCrown Bioscience, a JSR Life Sciences company and global CRO, specializes in oncology and immuno-oncology drug discovery and development. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With 1,000 tumor organoid models and the largest commercially available PDX collection, our expertise spans in vivo, in vitro, ex vivo, and in silico methods. We operate multiple facilities in the US, Europe, and APAC, meeting the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). Forward-Looking StatementsThis press release contains forward-looking statements relating to the proposed acquisition and future business expectations. These statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially. Adicon undertakes no obligation to update forward-looking statements except as required by applicable law.For investor and media inquiries, please contact:Investor Relations DepartmentAdicon Holdings LimitedEmail: ir@adicon.com.cnTel: 0571-87779340Website: https://investor.adicon.com.cn/13/11/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comView original content: EQS NewsEQS
Thu, Nov 13
Spot Gold Surges 1% to $4,237/Oz While Spot Silver Rises 2% to $54/Oz as Traders Assess Rate Path After US Shutdown Ends
Spot gold surged 1% to $4,237/oz while spot silver rose 2% to $54.34/oz.Gold rose as traders turned their attention to the Federal Reserve’s interest-rate outlook following Washington’s reopening.US President Donald Trump signed legislation to end the longest government shutdown on record. However, ...Tiger News
Thu, Nov 13
Earnings Preview | Trip.com Q3 Revenue and Profit Both Increased, Accommodation and Transportation Ticketing as Core Drivers
Trip.com Group Limited will release its fiscal year 2025 Q3 earnings report on November 17 (before the US market opens). According to data from the Tiger International APP, Trip.com is expected to report total revenue of 18.16 billion RMB for Q3, representing a year-over-year growth of approximate...Tiger News
Thu, Nov 13
Alibaba Preps Big Revamp of Flagship AI App to Resemble ChatGPT
Alibaba is planning to make comprehensive improvements to its major mobile artificial intelligence applications in the coming months, aiming to bring them closer to OpenAI's ChatGPT. This is a crucial step in its larger-scale competitive strategy, designed to compete with rivals and ultimately gene...Tiger News
Thu, Nov 13
Crypto Daily | Circle Tumbles Amid Concern Lower Rates Will Slow Profit; Coinbase Follows Elon Musk to Texas
Crypto Daily is our column tracking crypto market trends, offering timely insights and valuable updates to keep you informed.Crypto NewsCircle Tumbles Amid Concern Lower Rates Will Slow ProfitShares of Circle tumbled 12.2% on Wednesday, the most since June, as concern that declining interest rates w...Tiger News
Thu, Nov 13
Home Control (1747.HK): Inheriting the Philips Legacy and Shaping the Future of Smart Health
Home Control (1747.HK): Inheriting the Philips Legacy and Shaping the Future of Smart HealthWith over three decades of expertise in smart control and IoT technologies, Home Control (1747.HK) is steadily demonstrating a robust and promising performance in the global connected technology space. Backed by deep international roots and a comprehensive global footprint, the company is translating its engineering heritage into a sustainable growth trajectory.Originating from the home control division of Dutch electronics giant Philips, the company has inherited a tradition of European engineering precision and quality excellence, focusing on the development and manufacturing of smart control and connectivity solutions. Today, it serves a global clientele that includes many of the world’s leading home appliance, telecommunications, and smart home brands.Global Expertise Anchored in Philips HeritageHome Control’s core team brings over 30 years of industry experience and a strong track record in smart control and IoT solutions for tier-one global brands. The company has delivered more than 1.5 billion control modules and devices to over 300 customers worldwide, covering more than 40 markets.By combining European technical discipline with Asian manufacturing efficiency, Home Control has built a strong reputation for reliability, innovation, and execution. This unique mix of cultures and capabilities has positioned the company as a trusted technology partner in the smart connectivity ecosystem.The leadership and R&D teams span Europe, the U.S., and Asia, bringing deep international experience from major electronics and IoT enterprises. Through a management model that blends global strategic vision with agile local execution, Home Control successfully merges European precision with Asian responsiveness. This structure enables the company to maintain operational stability and healthy margins even amid supply chain volatility — a clear reflection of its maturity and resilience as an international player.A Global R&D and Manufacturing NetworkHome Control operates dual R&D centers in Singapore and China, each with a distinct focus:The Singapore team specializes in fundamental engineering and system architecture, averaging over two decades of industry experience. The China R&D center focuses on customized product development and commercial deployment, ensuring rapid turnaround from concept to production.In addition, the company runs manufacturing facilities across Mainland China, Brazil, India, and Cambodia, forming a diversified global production network. This distributed setup enhances flexibility, shortens delivery lead times, and mitigates regional supply chain risks — providing a solid foundation for sustainable global operations.Expanding from Smart Homes to Smart HealthSince 2019, Home Control has been expanding into the healthcare technology sector, delivering a notable performance in 2024 and continuing its growth momentum into 2025. In September 2025, the company established its Hong Kong subsidiary, Orbiva, to spearhead its entry into the home health segment. The initiative focuses on developing a data- and connectivity-driven health management ecosystem.Orbiva’s long-term vision is to build a people-centric, technology-driven global health services ecosystem, integrating AIoT technologies, medical resources, and innovative service models to achieve a seamless convergence of hardware, software, data, and services.This ecosystem will leverage Home Control’s established strengths in IoT technologies, software–hardware integration, and cross-disciplinary R&D capabilities, progressively launching smart health management and interactive devices, in-home health solutions, and a one-stop AIoT-based health data platform. By extending its expertise from smart control, sensing, and connectivity technologies, Home Control aims to build a “Connected Homes, Connected Health” ecosystem — positioning health innovation as a key growth engine for the company’s next phase of development. According to market projections, the global healthcare IT market is expected to grow from USD 588 billion in 2025 to USD 1.23 trillion by 2029, representing a compound annual growth rate of 20.2%. Asian governments are also accelerating healthcare digitalization — from China’s Healthy China 2030 plan to Singapore’s national electronic health record program — creating substantial demand for smart healthcare devices and connected medical systems.With its deep IoT capabilities and proven record of cross-sector collaboration, Home Control is well-positioned to capture early opportunities in this fast-growing segment and unlock a new phase of strategic growth.From Philips Heritage to the New Frontier of Health TechnologyFrom its Philips heritage to today’s globalized operations, Home Control has consistently focused on innovation, quality, and agility. As the boundaries between AIoT and digital healthcare continue to blur, the company stands at the intersection of two transformative industries — intelligent manufacturing and smart health.For long-term investors, Home Control represents a rare combination of European engineering DNA, international management depth, and Asian execution efficiency. As the company advances its transition from smart home solutions to connected health technologies, it may be entering a new cycle of revaluation and value creation in the global market.13/11/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comView original content: EQS NewsEQS
Thu, Nov 13
Cathie Wood Dumps $30 Million Worth of Tesla Stock Amid China Sales Slump, Loads up Circle and This Hot Chinese AI Stock
On Wednesday,Cathie Wood-led Ark Invest executed significant trades involvingCircle,Alibaba Group, andTesla. These trades reflect Ark’s strategic positioning in the market, with notable buys in Circle and Alibaba, and a sell-off in Tesla.The TSLA Trade:Ark Invest reduced its holdings inTeslaby selli...Tiger News
Thu, Nov 13
Shutdown’s End Will Kick Off Long Process of Rebooting US Government
The longest government shutdown in US history is coming to an end, but it could take days — and in some cases a week or more — before normal operations resume.Payroll systems must be updated to pay out weeks of back wages. Backlogs of grant disbursements, loan applications and customer calls that we...Tiger News
Thu, Nov 13
HK Movers | Auntea Jenny Jumps Another 10% After Soaring 29%
Auntea Jenny shares jumped another 10% in Hong Kong.Auntea Jenny shares surged 29% on Wednesday after the company announced its H-Share incentive plan and sub-brand Tea Waterfall revealed Mao Buyi as its brand ambassador.Auntea Jenny recently issued a statement indicating its intention to adopt a te...Tiger News
Thu, Nov 13
Samsonite's Q3 Net Profit Increases 11%, Gross Margin Rises to 59.6%
Samsonite shares surged over 19% in Hong Kong as Q3 net profit increased by 11%, with a gross margin rising to 59.6%.On the evening of November 12, Samsonite announced the results for the nine months ended September 30, 2025. The group reported a net sales of USD 2.534 billion, a 4.2% decrease year-...Tiger News
Thu, Nov 13
HK Movers | Star Plus Legend Plunges 19% as It Proposes HK$369 Million Fundraising via Top-Up Placement
"Jay Chou Concept Stock" Star Plus Legend announced that on November 13, 2025, the company, the vendors, and the placing agents entered into a placing and subscription agreement, under which (a) the vendors agreed to appoint the placing agents, and the placing agents agreed to procure buyers on a be...Tiger News
Thu, Nov 13
24H｜Cellebrite Surged 22%; Cisco Rose 7%; Ardent Health Tumbled 29%; Bitdeer And Dlocal Fell 15%
Cellebrite shares surged 22% in overnight trading after the digital investigation solutions provider reported third-quarter earnings that significantly exceeded analyst expectations, driven by strong subscription revenue growth.Cisco raised its forecast for full-year profit and revenue on Wednesday,...Tiger News
Thu, Nov 13
Featured Tools
Top News
Meta Connect 2026 New Product Roundup: Muse Integrated Into AI Glasses, Can It Drive Meta Revenue Growth?
US Stocks Mixed as Dow Drops 160 Points; Tech Stocks Lead, Meta Rises 4.5%
Meta Stock Forecast: Muse Monetization Path Is Key as JPMorgan Raises Price Target to $920; Can Stock Hit Record High?
Micron Earnings Preview: Five Key Things Memory Investors Need to Watch
【US Pre-Market】Nasdaq Leads Losses in Three Major Stock Index Futures, IONQ Surges Over 11%, RGTI Rises Over 5% as Market Focuses on US-China Summit
